Shattuck Labs, Inc. Share Price

Shattuck Labs, Inc. Share Price

NASDAQ: STTK | Small Cap
$5.90
+$0.11 (1.81%) Last updated on 29 Oct, 2026 | 19:54 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Shattuck Labs, Inc. Stock Performance

Open
$5.90
Prev. Close
$5.79
Circuit Range
N/A
Day Range
$5.83 - $5.92
Year Range
$1.80 - $8.30
Volume
4,593
Average Traded
$5.90

Shattuck Labs, Inc. Share Price Today

As of 29 October 2026, Shattuck Labs, Inc.'s share price is $5.90. The stock opened at $5.90, compared to its previous close of $5.79. During today's trading session, Shattuck Labs, Inc.'s share price traded between $5.83 and $5.92, with an average price of $5.88. Over the past 52 weeks, the stock has recorded a high of $8.30 and a low of $1.80. In terms of performance, Shattuck Labs, Inc.'s share price has declined by 17.25% over the last six months and is up 210.53% on a year-on-year basis.

Shattuck Labs, Inc. Share Price Chart

Line chart of the Shattuck Labs, Inc. price trend over the selected period. The price rose overall, ranging from 5.80 to 5.95, ending at 5.90.
$5.83$5.92
L
Show Current Price
H

Shattuck Labs, Inc. Stock Fundamentals & Key Indicators

Market Cap
$410.55M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-0.52
Revenue (TTM)
$1.00B
Return On Equity (TTM)
-24.90%
Profit Margin
-4881.00%
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-50.60%

Shattuck Labs, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$1.00$0.00$0.00$0.00
Net Profit-$10.06-$12.59-$14.77-$15.15
Net Profit Margin-1006.00%N/AN/AN/A
Income ChangeN/A-25.15%-17.32%-2.57%

Shattuck Labs, Inc. Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.65$1.66$5.72$1.00
Net Profit-$101.95-$87.30-$75.41-$48.81
Net Profit Margin-15684.62%-5259.04%-1318.36%-4881.00%
Income ChangeN/A14.37%13.62%35.27%

About Shattuck Labs, Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Shattuck Labs, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$6.74
$5.90
-14.55%
Sep 2026
$6.97
$6.91
-9.74%
Aug 2026
$7.06
$7.65
+8.28%
Jul 2026
$7.04
$7.07
+1.95%
Jun 2026
$5.90
$6.93
+16.67%
May 2026
$7.10
$5.94
-16.69%
Apr 2026
$6.58
$7.13
+10.80%
Mar 2026
$3.85
$6.43
+63.95%
Feb 2026
$3.77
$3.92
+1.16%
Jan 2026
$3.66
$3.88
+6.59%
Dec 2025
$2.34
$3.64
+74.58%
Nov 2025
$1.97
$2.08
+9.74%

STTK Share Price FAQs